Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer-Reference-Cited by-同舟云学术

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer

Published:2023-05-23 Issue:11 Volume:66 Page:7438-7453
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ma Lin¹,Li Yingying¹,Luo Ruixiang¹,Wang Yuhan¹,Cao Jiaqi¹,Fu Weitao²,Qian Bolan¹,Zheng Lei¹,Tang Longguang³,Lv Xinting¹,Zheng Lulu⁴,Liang Guang¹,Chen Lingfeng¹^ORCID

Affiliation:

1. Affiliated Yongkang First People’s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310012 Zhejiang, China

2. Department of Computer-Aided Drug Design, Jiangsu Vcare PharmaTech Co. Ltd., Nanjing 211800, China

3. International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang 322000, China

4. Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310000, China

Funder

Medical and Health Research Project of Zhejiang Province

National Natural Science Foundation of China

Department of Health of Zhejiang Province

Natural Science Foundation of Zhejiang Province

Zhejiang Provincial Key Scientific Project

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00150

Reference53 articles.

1. The FGF family: biology, pathophysiology and therapy

2. FGF Receptors: Cancer Biology and Therapeutics

3. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation

4. Cellular signaling by fibroblast growth factor receptors

5. Advances and challenges in targeting FGFR signalling in cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer;European Journal of Medicinal Chemistry;2024-11

2. Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor;European Journal of Medicinal Chemistry;2024-09

3. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

4. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer;Biomedicines;2024-05-17

5. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases;Journal of Medicinal Chemistry;2024-05-09